CD274 and cancer: Hence, our study reveals a novel molecular mechanism for regulating PD-L1 levels by an RNA-binding protein, which has the potential for developing combinatorial cancer immunotherapies against human TNBC by combining RBMS1 depletion with CTLA4 immune checkpoint blockade or CAR-T therapy.